Novosanis, an innovative developer and producer of medical devices, announced that it signed an agreement with MDxHealth to supply UrNCollect, a customized version of the company’s patented urine collection device called Colli-Pee. The medical device facilitates accurate sample collection for urine-based tests.
Novosanis, and MDxHealth SA signed a supply agreement for a customized version of Novosanis’ first void urine collection device, Colli-Pee. The device allows for a standardized, hygienic and user-friendly collection of the first 20ml of the urine stream and reduces lab errors by automating preservative mixing without additional handling.
Colli-Pee is a patented sampling device suited for standardized and guaranteed collection of first-void urine (first 20ml of the urine flow) allowing improved detection of infectious diseases as well as early stage cancer. Colli-Pee is in a commercial stage. It is CE-marked and FDA listed.
“We are happy to initiate a collaboration with MDxHealth. Our Colli-Pee device will allow easy collection of standardized first void urine with less handling and no traditional pipetting. Everybody gains when the sample collection process is simplified and streamlined.” said Dr. Vanessa Vankerckhoven, CEO and co-founder of Novosanis.
Dr. Jan Groen, CEO MDxHealth, commented: “MDxHealth is pleased with Novosanis’ development of UrNCollect for our SelectMDx for Prostate Cancer IVD kit that will launch later this year. We expect the device to be more comfortable for patients and contribute to the test’s accuracy.”
Novosanis is an innovative developer and producer of medical devices adding value to the accuracy of diagnostics tests as well as drug delivery in the field of prevention, detection and treatment of infectious diseases and oncology.
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.